CLSD vs. ATYR

Last updated Apr 1, 2026

Compare and contrast key facts about Clearside Biomedical, Inc. (CLSD) and aTyr Pharma, Inc. (ATYR).

Performance

CLSD vs. ATYR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Clearside Biomedical, Inc. (CLSD) and aTyr Pharma, Inc. (ATYR). The values are adjusted to include any dividend payments, if applicable.

CLSD vs. ATYR - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CLSD Clearside Biomedical, Inc.	0.00%	-97.12%	-18.80%	4.46%	-59.27%	0.36%	-5.52%	171.03%	-84.71%	-21.70%
ATYR aTyr Pharma, Inc.	-0.40%	-78.37%	156.74%	-35.62%	-70.68%	92.53%	-6.95%	-39.91%	-85.84%	62.79%

Fundamentals

EPS CLSD : -$4.99 ATYR : -$0.80
PS Ratio CLSD : 0.64 ATYR : 384.40
Total Revenue (TTM) CLSD : $3.33M ATYR : $190.00K
Gross Profit (TTM) CLSD : $2.85M ATYR : -$34.17M
EBITDA (TTM) CLSD : -$14.37M ATYR : -$76.54M

Returns By Period

CLSD

• 1D: 0.00%
• 1M: 0.00%
• YTD: 0.00%
• 6M: -89.67%
• 1Y: -97.02%
• 3Y*: -70.27%
• 5Y*: -59.50%
• 10Y*: —

ATYR

• 1D: 6.72%
• 1M: -18.73%
• YTD: -0.40%
• 6M: 8.12%
• 1Y: -74.17%
• 3Y*: -28.12%
• 5Y*: -29.78%
• 10Y*: -34.46%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CLSD vs. ATYR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CLSD

CLSD Risk / Return Rank: 4
CLSD Sharpe Ratio Rank: 12
CLSD Sortino Ratio Rank: 1
CLSD Omega Ratio Rank: 0
CLSD Calmar Ratio Rank: 2
CLSD Martin Ratio Rank: 6

ATYR

ATYR Risk / Return Rank: 21
ATYR Sharpe Ratio Rank: 15
ATYR Sortino Ratio Rank: 29
ATYR Omega Ratio Rank: 29
ATYR Calmar Ratio Rank: 11
ATYR Martin Ratio Rank: 20

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CLSD vs. ATYR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Clearside Biomedical, Inc. (CLSD) and aTyr Pharma, Inc. (ATYR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CLSD	ATYR	Difference
Sharpe ratio Return per unit of total volatility	-0.69	-0.61	-0.08
Sortino ratio Return per unit of downside risk	-2.65	-0.03	-2.62
Omega ratio Gain probability vs. loss probability	0.56	1.00	-0.44
Calmar ratio Return relative to maximum drawdown	-0.99	-0.83	-0.16
Martin ratio Return relative to average drawdown	-1.62	-1.16	-0.47
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CLSD vs. ATYR - Sharpe Ratio Comparison

The current CLSD Sharpe Ratio is -0.69, which is comparable to the ATYR Sharpe Ratio of -0.61. The chart below compares the historical Sharpe Ratios of CLSD and ATYR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CLSD	ATYR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.69	-0.61	-0.08
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.65	-0.36	-0.29
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.40	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.47	-0.46	0.00

Correlation

The correlation between CLSD and ATYR is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CLSD vs. ATYR - Dividend Comparison

Neither CLSD nor ATYR has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CLSD vs. ATYR - Drawdown Comparison

The maximum CLSD drawdown since its inception was -99.89%, roughly equal to the maximum ATYR drawdown of -99.83%. Use the drawdown chart below to compare losses from any high point for CLSD and ATYR.

Drawdown Indicators

	CLSD	ATYR	Difference
Max Drawdown Largest peak-to-trough decline	-99.89%	-99.83%	-0.06%
Max Drawdown (1Y) Largest decline over 1 year	-97.06%	-90.15%	-6.91%
Max Drawdown (5Y) Largest decline over 5 years	-99.62%	-94.78%	-4.84%
Max Drawdown (10Y) Largest decline over 10 years	—	-99.26%	—
Current Drawdown Current decline from peak	-99.89%	-99.80%	-0.09%
Average Drawdown Average peak-to-trough decline	-83.46%	-93.07%	+9.61%
Ulcer Index Depth and duration of drawdowns from previous peaks	59.81%	64.91%	-5.10%

Volatility

CLSD vs. ATYR - Volatility Comparison

The current volatility for Clearside Biomedical, Inc. (CLSD) is 0.00%, while aTyr Pharma, Inc. (ATYR) has a volatility of 21.76%. This indicates that CLSD experiences smaller price fluctuations and is considered to be less risky than ATYR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CLSD	ATYR	Difference
Volatility (1M) Calculated over the trailing 1-month period	0.00%	21.76%	-21.76%
Volatility (6M) Calculated over the trailing 6-month period	143.04%	61.00%	+82.04%
Volatility (1Y) Calculated over the trailing 1-year period	142.91%	121.55%	+21.36%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	94.42%	83.77%	+10.65%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	94.52%	85.40%	+9.12%

Financials